



\*Please note that this translation is to be used solely as reference.  
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.

# Supplementary Information of Consolidated Financial Results for ended March 31, 2026 (Updated Hard Backlog information)

---


May 22, 2026  
Linical Co., Ltd.

# Hard Backlog by Region



\* Hard backlog:

The balance of the amount for orders for contract business already concluded. This is an indicator that shows the amount of sales to be generated over the next one to five years and serves as the basis for the group's future results forecasts.



- Of the projects that were described as being in contract execution procedures in the earnings announcement dated May 15, 2026, contracts for two projects have been completed.
- Reflecting these completions, hard backlog as of May 22, 2026 totaled 13.0 billion yen, representing a 10.9% increase compared to the end of March 2025.

# Hard Backlog in each region

(Comparison between May 22, 2026 and end of March 2025)



## ■ Japan and Asia:

- Compared to the end of March 2025, hard backlog decreased in Japan, but increased in Asia due to the acquisition of multiple new orders
- Increasing trend in wins for global clinical trial projects from US/European biotechs covering Japan and Asia, as well as development projects from Japanese and Asian pharma and biotech companies targeting market entry via Australia or direct access to North America.

## ■ US:

- Hard backlog increased compared to the end of March 2025 due to the completion of contracts for multiple large-scale global clinical trials covering the United States, Europe, and Australia, as well as the completion of scope change orders that increased workload, and the completion of contracts for new projects mainly to be conducted in the United States. Continue to strengthen sales and proposal activities to win orders, as there are many inquiries for new projects, including global projects.

## ■ Europe:

- Hard backlog increased compared to the end of March 2025 due to the increase in hard backlog from change orders for existing projects, the increase in hard backlog from the recognition of the European portion of the large-scale global clinical trials won by the US, as mentioned above, and the completion of contracts for multiple new projects mainly to be conducted in Europe.
- Expanding project wins from US companies, including Europe-related projects, through enhanced collaboration with our US operations, while strengthening our European sales presence.

# Cautionary Notes

---



Those plans, forecasts, strategies, etc., stated in this document that are not historical facts are forecasts concerning future results. These are forecasts that have been determined by the company based on information currently available so please do not place undue reliance on them.

Please understand that the company will bear no responsibility whatsoever for any damage, etc., resulting from errors in the information stated in this document. In addition, this document is not aimed at soliciting investment.

Users are asked to make investment decisions at their own judgment.